HLPA
2021-12-17
Both will plunge deeper
2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.<blockquote>2家生物技术公司周四开始交易。一个跳了下去，另一个跳了下去。</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":699053003,"tweetId":"699053003","gmtCreate":1639726733824,"gmtModify":1639726734574,"author":{"id":3569274903458035,"idStr":"3569274903458035","authorId":3569274903458035,"authorIdStr":"3569274903458035","name":"HLPA","avatar":"https://static.tigerbbs.com/07e7b987a9127c5a47dbc3ae02db548b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":66,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Both will plunge deeper</p></body></html>","htmlText":"<html><head></head><body><p>Both will plunge deeper</p></body></html>","text":"Both will plunge deeper","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/699053003","repostId":1131183374,"repostType":4,"repost":{"id":"1131183374","kind":"news","pubTimestamp":1639724439,"share":"https://www.laohu8.com/m/news/1131183374?lang=zh_CN&edition=full","pubTime":"2021-12-17 15:00","market":"us","language":"en","title":"2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.<blockquote>2家生物技术公司周四开始交易。一个跳了下去，另一个跳了下去。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183374","media":"Barrons","summary":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly","content":"<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p><p><blockquote>在生物技术公司Immix Biopharma股价较发行价下跌近27%后，IPO市场将于2021年结束。</blockquote></p><p> Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p><p><blockquote>Immix（股票代码：IMMX）是本周第三家交易价格低于首次公开募股价格的公司。周三，生物技术公司Genenta Science(GNTA)下跌超过4%，而低碳水化合物葡萄酒生产商Fresh Vine Wine(VINE)前一天暴跌近30%。</blockquote></p><p> Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p><p><blockquote>Bionomics(BNOX)周四也开盘，股价上涨超过19%。该生物技术公司不被视为首次公开募股，因为其股票已在澳大利亚证券交易所交易。</blockquote></p><p> IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p><p><blockquote>12月份IPO大幅放缓。Dealogic表示，本月已有10家公司通过传统IPO上市，筹集了49亿美元。相比之下，去年有21家公司通过传统发行上市，筹集了128亿美元。</blockquote></p><p> The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p><p><blockquote>预计下周IPO市场将因假期而休息，许多交易将被搁置。新发行预计将于1月中旬重新发行。预计周五不会有公司通过传统发行方式上市。</blockquote></p><p> Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p><p><blockquote>包括Immix和Bionomics在内的六家公司本周已经为他们的交易定价。卫星公司Sidus Space(SIDU)的股价周二飙升近144%，表现强劲。周三，物联网公司Samsara（IOT）的股票上涨了7%以上。</blockquote></p><p> Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p><p><blockquote>Immix股价开盘价为5美元，随后下跌。该股收于3.67美元，较发行价下跌1.33美元。</blockquote></p><p> Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p><p><blockquote>Immix正在开发组织特异性疗法来治疗癌症和炎症。招股说明书称，其主要候选产品IMX-110目前正在美国和澳大利亚进行实体瘤的1b/2a期临床试验。</blockquote></p><p> Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p><p><blockquote>Immix将交易规模扩大至420万股，以每股5美元的价格出售。这家洛杉矶公司原计划以每股5至6美元的价格出售约383万股股票。</blockquote></p><p> Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p><p><blockquote>与此同时，Bionomcis的股价开盘价为22美元，收盘价为14.73美元，较发行价上涨2.38美分。</blockquote></p><p> Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p><p><blockquote>Bionomics正在为患有严重中枢神经系统疾病的人开发疗法。根据招股说明书，其主要候选产品BNC210可治疗社交焦虑症和创伤后应激障碍。</blockquote></p><p> Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p><p><blockquote>Bionomics以每股12.35美元的价格出售了162万股美国存托股票(ADS)。每股美国存托凭证代表180股Bionomics普通股。</blockquote></p><p></p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.<blockquote>2家生物技术公司周四开始交易。一个跳了下去，另一个跳了下去。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotechs Began Trading Thursday. One Jumped, the Other Plunged.<blockquote>2家生物技术公司周四开始交易。一个跳了下去，另一个跳了下去。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-12-17 15:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.</p><p><blockquote>在生物技术公司Immix Biopharma股价较发行价下跌近27%后，IPO市场将于2021年结束。</blockquote></p><p> Immix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.</p><p><blockquote>Immix（股票代码：IMMX）是本周第三家交易价格低于首次公开募股价格的公司。周三，生物技术公司Genenta Science(GNTA)下跌超过4%，而低碳水化合物葡萄酒生产商Fresh Vine Wine(VINE)前一天暴跌近30%。</blockquote></p><p> Bionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.</p><p><blockquote>Bionomics(BNOX)周四也开盘，股价上涨超过19%。该生物技术公司不被视为首次公开募股，因为其股票已在澳大利亚证券交易所交易。</blockquote></p><p> IPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.</p><p><blockquote>12月份IPO大幅放缓。Dealogic表示，本月已有10家公司通过传统IPO上市，筹集了49亿美元。相比之下，去年有21家公司通过传统发行上市，筹集了128亿美元。</blockquote></p><p> The IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.</p><p><blockquote>预计下周IPO市场将因假期而休息，许多交易将被搁置。新发行预计将于1月中旬重新发行。预计周五不会有公司通过传统发行方式上市。</blockquote></p><p> Six companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.</p><p><blockquote>包括Immix和Bionomics在内的六家公司本周已经为他们的交易定价。卫星公司Sidus Space(SIDU)的股价周二飙升近144%，表现强劲。周三，物联网公司Samsara（IOT）的股票上涨了7%以上。</blockquote></p><p> Shares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.</p><p><blockquote>Immix股价开盘价为5美元，随后下跌。该股收于3.67美元，较发行价下跌1.33美元。</blockquote></p><p> Immix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.</p><p><blockquote>Immix正在开发组织特异性疗法来治疗癌症和炎症。招股说明书称，其主要候选产品IMX-110目前正在美国和澳大利亚进行实体瘤的1b/2a期临床试验。</blockquote></p><p> Immix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.</p><p><blockquote>Immix将交易规模扩大至420万股，以每股5美元的价格出售。这家洛杉矶公司原计划以每股5至6美元的价格出售约383万股股票。</blockquote></p><p> Shares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.</p><p><blockquote>与此同时，Bionomcis的股价开盘价为22美元，收盘价为14.73美元，较发行价上涨2.38美分。</blockquote></p><p> Bionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.</p><p><blockquote>Bionomics正在为患有严重中枢神经系统疾病的人开发疗法。根据招股说明书，其主要候选产品BNC210可治疗社交焦虑症和创伤后应激障碍。</blockquote></p><p> Bionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.</p><p><blockquote>Bionomics以每股12.35美元的价格出售了162万股美国存托股票(ADS)。每股美国存托凭证代表180股Bionomics普通股。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNOX":"Bionomics Limited","IMMX":"Immix Biopharma, Inc"},"source_url":"https://www.marketwatch.com/articles/two-biotech-ipos-set-to-start-trading-on-thursday-51639676485?mod=newsviewer_click_seemore","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1131183374","content_text":"The IPO market is set to close out 2021 with a thud after Immix Biopharma, a biotech, dropped nearly 27% below its offer price.\nImmix (ticker: IMMX) is the third company this week to trade below its initial public offering price. On Wednesday, Genenta Science (GNTA), a biotech, fell more than 4%, while Fresh Vine Wine (VINE), a producer of low-carb wine, plunged nearly 30% the day before.\nBionomics (BNOX) also opened on Thursday, with shares rising more than 19%. The biotech is not considered an IPO since its stock already trades on the Australian Securities Exchange.\nIPOs have slowed considerably in December. Ten companies have gone public this month in traditional IPOs, raising $4.9 billion, Dealogic said. This compares to last year, when 21 companies listed their shares using traditional offerings, collecting $12.8 billion.\nThe IPO market is expected to go on break next week for the holidays, with many deals going on hold. New issues are expected to reopen in mid-January. No companies are expected to go public on Friday using a traditional offering.\nSix companies, including Immix and Bionomics, have priced their deals this week. Sidus Space (SIDU), a satellite company, turned in a strong performance when its stock rocketed nearly 144% Tuesday. On Wednesday, the stock of Samsara (IOT), an internet of things company, rose more than 7%.\nShares of Immix opened at $5 and dropped. The stock closed at $3.67, down $1.33 from its offer price.\nImmix is developing tissue-specific therapeutics to treat cancer and inflammation. Its lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia, a prospectus said.\nImmix increased the size of its deal to $4.2 million shares, which it sold at $5 each. The Los Angeles company had planned on selling roughly 3.83 million shares at $5 to $6 each.\nShares of Bionomcis, meanwhile, opened at $22 and ended at $14.73, up $2.38 cents from its offer price.\nBionomics is developing therapies for persons suffering from serious central nervous system disorders. Its lead product candidate, BNC210, treats social anxiety disorder and post-traumatic stress disorder, according to a prospectus.\nBionomics sold 1.62 million American Depositary Shares, or ADSs, at $12.35 a share. Each ADS represents 180 ordinary shares of Bionomics.","news_type":1,"symbols_score_info":{"BNOX":0.9,"IMMX":0.9}},"isVote":1,"tweetType":1,"viewCount":2700,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/699053003"}
精彩评论